Security Name | Ticker | % of Net Assets |
---|---|---|
ABBVIE INC | ABBV | 6.66% |
AMGEN INC. | AMGN | 4.49% |
GILEAD SCIENCES, INC. | GILD | 4.47% |
VERTEX PHARMACEUTICALS | VRTX | 3.96% |
REGENERON PHARMACEUTICALS | REGN | 3.52% |
CORTEVA INC | CTVA | 3.44% |
ALNYLAM PHARMACEUTICALS | ALNY | 3.14% |
NATERA INC | NTRA | 2.28% |
ASTRAZENECA PLC ADR | AZN | 2.10% |
INSMED INC | INSM | 2.05% |
ROYALTY PHARMA PLC- CL A | RPRX | 2.04% |
BEONE MEDICINES LTD-ADR | BGNE | 2.02% |
BIOGEN IDEC, INC. | BIIB | 2.00% |
ILLUMINA INC | ILMN | 1.89% |
UNITED THERAPEUTICS CORP | UTHR | 1.68% |
NEUROCRINE BIOSCIENCES IN | NBIX | 1.67% |
EXELIXIS, INC. | EXEL | 1.65% |
INCYTE CORP | INCY | 1.57% |
VIATRIS INC | VTRS | 1.54% |
EXACT SCIENCES | EXAS | 1.52% |
BIOMARIN PHARMACEUTICAL | BMRN | 1.51% |
MODERNA INC | MRNA | 1.46% |
JAZZ PHARMACEUTICALS PLC | JAZZ | 1.40% |
BRIDGEBIO PHARMA INC | BBIO | 1.39% |
BLUEPRINT MEDICI | BPMC | 1.36% |
ARGENX SE - ADR | ARGX | 1.26% |
IONIS PHARMACEUTICALS, IN | IONS | 1.25% |
CRISPR THERAPEUTICS AG | CRSP | 1.25% |
GUARDANT HEALTH INC | GH | 1.20% |
HALOZYME THERAPEUTICS INC | HALO | 1.18% |
BIONTECH SE-ADR | BNTX | 1.17% |
REVOLUTION MEDICINES INC | RVMD | 1.14% |
LEGEND BIOTECH CORP-ADR | LEGN | 1.12% |
ALKERMES PLC | ALKS | 1.11% |
TG THERAPEUTICS | TGTX | 1.08% |
MEDPACE HOLDINGS | MEDP | 1.05% |
ROIVANT SCIENCES LTD | ROIV | 1.02% |
AKERO THERAPEUTICS INC | AKRO | 1.00% |
PTC THERAPEUTICS | PTCT | 0.93% |
VAXCYTE INC | PCVX | 0.93% |
CYTOKINETICS INC | CYTK | 0.93% |
ADMA BIOLOGICS INC | ADMA | 0.91% |
SPRINGWORKS THERAPEUTICS | SWTX | 0.88% |
PROTAGONIST THER | PTGX | 0.87% |
AVIDITY BIOSCIENCES INC | RNA | 0.83% |
ACADIA PHARMACEUTICALS IN | ACAD | 0.80% |
ULTRAGENYX PHARM | RARE | 0.80% |
AXSOME THERAPEUT | AXSM | 0.78% |
VIKING THERAPEUTICS INC | VKTX | 0.77% |
VERACYTE INC | VCYT | 0.72% |
TWIST BIOSCIENCE CORP | TWST | 0.71% |
NUVALENT INC-A | NUVL | 0.69% |
KRYSTAL BIOTECH INC | KRYS | 0.68% |
CRINETICS PHARMACEUTICALS | CRNX | 0.67% |
ARROWHEAD PHARMACEUTICALS | ARWR | 0.66% |
RECURSION PHARMACEUTICALS | RXRX | 0.65% |
AGIOS PHARMACEUT | AGIO | 0.63% |
AMICUS THERAPEUTICS INC | FOLD | 0.63% |
APELLIS PHARMACE | APLS | 0.63% |
IDEAYA BIOSCIENCES INC | IDYA | 0.62% |
SUMMIT THERAPEUTICS INC | SMMT | 0.61% |
BEAM THERAPEUTICS INC | BEAM | 0.59% |
DENALI THERAPEUT | DNLI | 0.58% |
ASCENDIS PHA-ADR | ASND | 0.58% |
CELLDEX THERAPEUTICS INC | CLDX | 0.56% |
ARCELLX INC | ACLX | 0.56% |
MADRIGAL PHARMAC | MDGL | 0.56% |
IMMUNOVANT INC | IMVT | 0.51% |
DYNAVAX TECHNOLOGY | DVAX | 0.50% |
INTELLIA THERAPE | NTLA | 0.50% |
NOVAVAX INC | NVAX | 0.44% |
SAREPTA THERAPEU | SRPT | 0.41% |
DYNE THERAPEUTICS INC | DYN | 0.38% |
GERON CORP | GERN | 0.22% |
IOVANCE BIOTHERAPEUTICS | IOVA | 0.20% |
Other (Cash, derivatives and other liabilities) | 0.44% | |
Total: |
Read a prospectus and summary prospectus (if available) carefully before investing. It contains the investment objective, risks charges, expenses and the other information, which should be considered carefully before investing. To obtain a prospectus and summary prospectus (if available) click here or call 800.820.0888.
Investing involves risk, including the possible loss of principal.
Guggenheim Investments represents the following affiliated investment management businesses of Guggenheim Partners, LLC: Guggenheim Partners Investment Management, LLC, Security Investors, LLC, Guggenheim Funds Distributors, LLC, Guggenheim Funds Investment Advisors, LLC, Guggenheim Corporate Funding, LLC, Guggenheim Wealth Solutions, LLC, Guggenheim Partners Europe Limited, Guggenheim Partners Japan Limited, GS GAMMA Advisors, LLC, and Guggenheim Private Investments, LLC.
© 2025 Guggenheim Investments. All Rights Reserved.
Research our firm with FINRA Broker Check.
• Not FDIC Insured • No Bank Guarantee • May Lose Value
This website is directed to and intended for use by citizens or residents of the United States of America only. The material provided on this website is not intended as a recommendation or as investment advice of any kind, including in connection with rollovers, transfers, and distributions. Such material is not provided in a fiduciary capacity, may not be relied upon for or in connection with the making of investment decisions, and does not constitute a solicitation of an offer to buy or sell securities. All content has been provided for informational or educational purposes only and is not intended to be and should not be construed as legal or tax advice and/or a legal opinion. Always consult a financial, tax and/or legal professional regarding your specific situation. Investing involves risk, including the possible loss of principal.